Iruplinalkib, a new-generation drug, was approved by NMPA in 2023 to treat crizotinib-resistant or intolerant, locally advanced, metastatic ALK + NSCLC (Yang et al., 2023). The gene discussed is ALK; the disease is non-small cell lung carcinoma.